My Medical Gateway News

If you’re searching for private treatment in the UK, you’re likely facing high costs and long waits. This blog explains why thousands of patients are now choosing Europe for the five most in-demand orthopaedic procedures, including knee, hip and spinal surgery. With significantly lower prices and the ability to secure surgery dates within weeks, MMG offers a faster, more affordable route to treatment and a quicker return to normal life.

For patients in England searching online for private treatment, orthopaedics dominates the landscape. Chronic pain, reduced mobility and untreated injuries are pushing increasing numbers of people to look beyond the NHS, yet what they encounter is a difficult trade-off. NHS waiting lists remain long, while private treatment in the UK is often prohibitively expensive. As a result, more patients are beginning to look outside the UK altogether, and when they do, the economics are hard to ignore.

At My Medical Gateway (MMG), the focus is on the five orthopaedic treatments that sit at the centre of this demand. These are not niche procedures. They are the core drivers of the UK elective backlog, and the data explains why patients are actively searching for alternatives.

Take total knee replacement. There are currently more than 49,000 patients on NHS waiting lists for this procedure, with average waiting times approaching 29 weeks. In reality, many patients wait far longer. For those considering private treatment, the cost in the UK typically ranges from £13,000 to over £15,000. In contrast, the average cost across EU hospitals is closer to £8,800, around 30 percent lower. For a patient in persistent pain, the decision becomes increasingly straightforward. Wait months or pay a premium or access the same procedure sooner at a materially lower cost.

Hip replacement follows almost exactly the same pattern. More than 31,000 patients are currently waiting, with comparable delays and similar levels of demand. The UK private price range sits between £12,500 and £15,000, while EU providers average just over £9,000. The clinical outcome is not the differentiator. The difference lies in price and access. For patients comparing options online, particularly those already considering private treatment, this gap is becoming increasingly difficult to justify.

Even in smaller categories such as shoulder replacement, the same structural imbalance persists. Waiting times can still extend to 20 to 30 weeks or more depending on the NHS Trust, while private pricing in the UK ranges from around £12,000 to £13,700. Across the EU, the average cost is closer to £8,800 . Although volumes are lower, the underlying issue remains unchanged. Patients are being asked to choose between delay and cost, when a third option is now available.

Spinal surgery introduces a different dimension. Here, urgency becomes the defining factor. Back pain and nerve-related conditions can severely limit day-to-day life, making extended waits impractical. Around 65,000 spinal procedures are carried out each year across the UK system , yet access remains uneven. Private treatment costs in the UK are in the region of £11,300, while EU providers average closer to £7,000, representing a gap of nearly 40 percent . For many patients, particularly those still working, the ability to return to normal life quickly outweighs all other considerations.

ACL reconstruction, typically affecting younger and more active patients, highlights a similar tension. NHS waiting times for this procedure can stretch from 40 to 60 weeks in many areas. While the price difference between the UK and EU is smaller, around £7,000 in the UK compared to just over £6,200 in Europe, cost is not the primary driver. Time is. For patients unable to work, train or maintain their lifestyle, waiting close to a year is not a viable option.

Across all five procedures, the pattern is consistent. NHS backlogs remain high, UK private treatment is expensive and there is significant high-quality capacity available across EU hospitals at lower prices. This is not a short-term distortion. It is a structural gap that is now visible to patients, particularly those actively searching for private treatment online.

What has been missing until now is a reliable way to act on that insight. Medical travel has traditionally been fragmented, with patients expected to navigate providers, pricing and logistics themselves. The risk has often outweighed the potential benefit.

MMG is designed to remove that friction. By working exclusively with accredited hospitals and structuring treatments into a fixed-price package, the platform allows patients to compare options across Europe on a like-for-like basis. Surgery, post-operative care and key logistics are bundled into a single, transparent price, removing uncertainty and making cross-border treatment a practical choice rather than a theoretical one.

Critically, MMG also addresses the question of speed. Once a patient has submitted their diagnostic data, their chosen hospital will review the case and provide three available treatment dates within a six-week window. This is not an indicative timeline, it is part of the operating model. For patients who may otherwise be facing months of uncertainty, this represents a rapid and predictable route to surgery, allowing them to resolve their condition and return to normal life, including work, far sooner than would be possible through traditional pathways.

For UK patients, the shift is already underway. As awareness grows, more people are recognising that they are not limited to the choice between the NHS and high-cost private care at home. There is a third option, one that offers faster access, lower pricing and a structured pathway that removes much of the uncertainty.

The demand for orthopaedic treatment in the UK is not going to decline. If anything, it will increase. The more relevant question is how patients respond to that demand. Increasingly, the answer lies beyond national borders, and MMG is positioned at the centre of that change.